Beta-lactam target attainment and associated outcomes in patients with bloodstream infections-Reference-Cited by-同舟云学术

Beta-lactam target attainment and associated outcomes in patients with bloodstream infections

Published:2023-03 Issue:3 Volume:61 Page:106727
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Alshaer Mohammad H.^ORCID,Maranchick Nicole,Alexander Kaitlin M.,Manigaba Kayihura,Shoulders Bethany R.^ORCID,Felton Timothy W.,Mathew Sumith K.,Peloquin Charles A.^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference27 articles.

1. The incidence and prognosis of patients with bacteremia;Nielsen;Dan Med J,2015

2. Attributable mortality of ICU acquired bloodstream infections: a propensity-score matched analysis;Massart;Eur J Clin Microbiol Infect Dis,2021

3. Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria;Thaden;Antimicrob Agents Chemother,2017

4. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections;Suárez;Expert Rev Anti Infect Ther,2005

5. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: a reappraisal;Garrouste-Orgeas;Clin Infect Dis,2006

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis;Journal of Global Antimicrobial Resistance;2024-12

2. An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients;Journal of Antimicrobial Chemotherapy;2024-08-19

3. Evaluation of pharmacokinetic pharmacodynamic target attainment of meropenem in pediatric patients;Pediatrics & Neonatology;2024-07

4. Pharmacokinetic/pharmacodynamic issues for optimizing treatment with beta-lactams of Gram-negative infections in critically ill orthotopic liver transplant recipients: a comprehensive review;Frontiers in Antibiotics;2024-06-17

5. Impact of attaining aggressive vs. conservative PK/PD target on the clinical efficacy of beta-lactams for the treatment of Gram-negative infections in the critically ill patients: a systematic review and meta-analysis;Critical Care;2024-04-16